Genertec Universal Medical Group (HKG:2666) Shareholders Booked A 13% Gain In The Last Three Years

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

While Genertec Universal Medical Group Company Limited (HKG:2666) shareholders are probably generally happy, the stock hasn’t had particularly good run recently, with the share price falling 14% in the last quarter. But at least the stock is up over the last three years. However, it’s unlikely many shareholders are elated with the share price gain of 13% over that time, given the rising market.

See our latest analysis for Genertec Universal Medical Group

There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.

Genertec Universal Medical Group was able to grow its EPS at 21% per year over three years, sending the share price higher. The average annual share price increase of 4.0% is actually lower than the EPS growth. Therefore, it seems the market has moderated its expectations for growth, somewhat. We’d venture the lowish P/E ratio of 6.92 also reflects the negative sentiment around the stock.

You can see how EPS has changed over time in the image below (click on the chart to see the exact values).

SEHK:2666 Past and Future Earnings, June 19th 2019
SEHK:2666 Past and Future Earnings, June 19th 2019

We consider it positive that insiders have made significant purchases in the last year. Even so, future earnings will be far more important to whether current shareholders make money. This free interactive report on Genertec Universal Medical Group’s earnings, revenue and cash flow is a great place to start, if you want to investigate the stock further.

What About Dividends?

As well as measuring the share price return, investors should also consider the total shareholder return (TSR). The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. It’s fair to say that the TSR gives a more complete picture for stocks that pay a dividend. As it happens, Genertec Universal Medical Group’s TSR for the last 3 years was 25%, which exceeds the share price return mentioned earlier. And there’s no prize for guessing that the dividend payments largely explain the divergence!

A Different Perspective

It’s nice to see that Genertec Universal Medical Group shareholders have gained 1.5% (in total) over the last year. That includes the value of the dividend. That falls short of the 7.7% it has made, for shareholders, each year, over three years. If you want to research this stock further, the data on insider buying is an obvious place to start. You can click here to see who has been buying shares – and the price they paid.

Genertec Universal Medical Group is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on HK exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.